Chen Jian-lin, Feng Kai, Guo Zi-Kuan, U Ren-na, Xu Chen, Li Yu-hang, Liu Xiao-dan, Mao Ning, Chen Hu
Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital of Chinese Academy of Military Medical Science, Hematopoietic Stem Cell Transplantation Center of PLA, Beijing 100039, China.
Zhonghua Xue Ye Xue Za Zhi. 2005 Dec;26(12):740-2.
To address the question whether bone marrow mesenchymal stem cells (MSCs) could lower responsiveness of allogeneic T lymphocytes against alloantigens, and explore a feasible strategy for prevention of graft versus host disease (GVHD) occurred in allogeneic bone marrow transplantation.
T cells were co-cultured with (60)Co-irradiated bone marrow MSCs from different individuals. The proliferative activity of T cells and their reactivity to allogeneic cells and ConA were evaluated with (3)H-TdR incorporation assay.
T cells could not be activated upon primary or even secondary exposure to allogeneic MSCs (compared the CPM value of 27,529 +/- 969 of T cell alone with that of primary and secondary exposures to allogeneic MSCs were 9,126 +/- 654 and 13,260 +/- 874, respectively). When MSCs were induced to express HLA-DR, they still could not elicit T cell activation. The proliferation rate of allogenous T cells exposed to MSCs was dramatically declined when T cells from the same donor's MSCs were used as stimulator (CPM value decreased from 45,876 +/- 5285 before coculture to 9850 +/- 1618 after coculture). Furthermore, the results remained unchanged even ConA was added into the culture system.
Heterogenetic MSCs could suppress T cell activation. MSCs pretreatment might be useful in the prevention of GVHD in HLA-mismatched bone marrow transplantation.
探讨骨髓间充质干细胞（MSCs）是否能降低同种异体T淋巴细胞对同种异体抗原的反应性，并探索预防同种异体骨髓移植中发生移植物抗宿主病（GVHD）的可行策略。
将T细胞与来自不同个体的经（60）Co照射的骨髓MSCs共培养。用（3）H-TdR掺入法评估T细胞的增殖活性及其对同种异体细胞和ConA的反应性。
T细胞在初次或再次接触同种异体MSCs时均未被激活（单独T细胞的CPM值为27,529±969，初次和再次接触同种异体MSCs时分别为9,126±654和13,260±874）。当MSCs被诱导表达HLA-DR时，它们仍然不能引发T细胞激活。当使用来自同一供体MSCs的T细胞作为刺激物时，暴露于MSCs的同种异体T细胞的增殖率显著下降（CPM值从共培养前的45,876±5285降至共培养后的9850±1618）。此外，即使在培养体系中加入ConA，结果也保持不变。
异种MSCs可抑制T细胞激活。MSCs预处理可能有助于预防HLA不匹配的骨髓移植中的GVHD。
